scholarly journals Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial

2016 ◽  
Vol 23 (2) ◽  
pp. 247-256 ◽  
Author(s):  
R E Frye ◽  
J Slattery ◽  
L Delhey ◽  
B Furgerson ◽  
T Strickland ◽  
...  
Keyword(s):  
Folinic Acid ◽  
Language Impairment ◽  
Controlled Trial ◽  
Children With Autism ◽  
Verbal Communication ◽  
Double Blind ◽  
Double Blind Placebo

A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism

2015 ◽  
Vol 229 (1-2) ◽  
pp. 181-187 ◽  
Author(s):  
Ali Ghaleiha ◽  
Soudeh Mohebbi Rasa ◽  
Mohammadali Nikoo ◽  
Mehdi Farokhnia ◽  
Mohammad-Reza Mohammadi ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Children With Autism ◽  
Adjunctive Treatment ◽  
Aberrant Behavior ◽  
Double Blind ◽  
Double Blind Placebo

Double-Blind, Placebo-Controlled Trial of Risperidone Plus Amantadine in Children With Autism

2013 ◽  
Vol 36 (6) ◽  
pp. 179-184 ◽  
Author(s):  
Mohammad-Reza Mohammadi ◽  
Nourrollah Yadegari ◽  
Elmira Hassanzadeh ◽  
Mehdi Farokhnia ◽  
Habibeh Yekehtaz ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Children With Autism ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. results of a multicenter randomized, double-blind, placebo-controlled trial

1993 ◽  
Vol 36 (6) ◽  
pp. 795-803 ◽  
Author(s):  
Jeffrey B. Shiroky ◽  
Carolyn Neville ◽  
John M. Esdaile ◽  
Denis Choquette ◽  
Michel Zummer ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Folinic Acid ◽  
Low Dose ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Dose Methotrexate

Double-blind placebo-controlled trial of pentoxifylline added to risperidone: Effects on aberrant behavior in children with autism

2010 ◽  
Vol 34 (1) ◽  
pp. 32-36 ◽  
Author(s):  
Shahin Akhondzadeh ◽  
Jalil Fallah ◽  
Mohammad-Reza Mohammadi ◽  
Reza Imani ◽  
Mohammad Mohammadi ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Children With Autism ◽  
Aberrant Behavior ◽  
Double Blind ◽  
Double Blind Placebo

Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial

2006 ◽  
Vol 37 (2) ◽  
pp. 367-373 ◽  
Author(s):  
Gahan J. Pandina ◽  
Cynthia A. Bossie ◽  
Eriene Youssef ◽  
Young Zhu ◽  
Fiona Dunbar
Keyword(s):  
Controlled Trial ◽  
Children With Autism ◽  
Behavioral Symptoms ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial

2013 ◽  
Vol 16 (4) ◽  
pp. 783-789 ◽  
Author(s):  
Ali Ghaleiha ◽  
Mahtab Asadabadi ◽  
Mohammad-Reza Mohammadi ◽  
Maryam Shahei ◽  
Mina Tabrizi ◽  
...  
Keyword(s):  
Side Effects ◽  
Controlled Trial ◽  
Neurodevelopmental Disorder ◽  
Children With Autism ◽  
Primary Outcome Measure ◽  
Adjunctive Treatment ◽  
Controlled Study ◽  
Double Blind ◽  
Aberrant Behavior Checklist ◽  
Double Blind Placebo

Abstract Autism is a neurodevelopmental disorder that causes significant impairment in socialization and communication. It is also associated with ritualistic and stereotypical behaviour. Recent studies propose both hyper-and hypoglutamatergic ideologies for autism. The objective of this study was to assess the effects of memantine plus risperidone in the treatment of children with autism. Children with autism were randomly allocated to risperidone plus memantine or placebo plus risperidone for a 10-wk, double-blind, placebo-controlled study. The dose of risperidone was titrated up to 3 mg/d and memantine was titrated to 20 mg/d. Children were assessed at baseline and after 2, 4, 6, 8 and 10 wk of starting medication protocol. The primary outcome measure was the irritability subscale of Aberrant Behavior Checklist–Community (ABC-C). Difference between the two treatment arms was significant as the group that received memantine had greater reduction in ABC-C subscale scores for irritability, stereotypic behaviour and hyperactivity. Eight side-effects were observed over the trial, out of the 25 side-effects that the checklist included. The difference between the two groups in the frequency of side-effects was not significant. The present study suggests that memantine may be a potential adjunctive treatment strategy for autism and it was generally well tolerated. This trial is registered with the Iranian Clinical Trials Registry (IRCT1138901151556N10; www.irct.ir)

Sign in / Sign up

Export Citation Format

Share Document